Datroway Extends Survival in Metastatic Triple-Negative Breast Cancer
Datroway demonstrated a significant improvement in overall survival and progression-free survival in a Phase III trial for patients with metastatic triple-negative breast cancer who cannot receive immunotherapy, marking a potential breakthrough in treatment options for this high-risk group.